Phaseline

Targets › NMDAR

NMDAR: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 4; Other, Genitourinary; next expected readout Jan 2027.

Open in Phaseline: the race on NMDAR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rawalpindi Institute of CardiologyKetamine-Propofol
NMDA receptor antagonist combined with GABA-A agonist
NMDAR, GABRA1Phase 4PropofolJan 2027
Peking University First HospitalIntranasal dexmedetomidine-esketamine
Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist
ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1Phase 4Adenotonsillectomy; General AnesthesiaFeb 2027

Conditions

Propofol (1) Adenotonsillectomy (1) General Anesthesia (1)

Modalities

small molecule (2)

Companies

Rawalpindi Institute of Cardiology (1) Peking University First Hospital (1)

Related targets

GABRA1 (1) ADRA2A (1) ADRA2B (1) ADRA2C (1) GRIN1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.